• Abbott (NYSE:ABT) shares are up ~5% in premarket trading Friday after a Missouri jury found that it and Reckitt Benckiser (OTCPK:RBGPF) were not liable for their baby formula products allegedly causing a severe bowel illness.
• Reckitt Benckiser (OTCPK:RBGLY) is up ~8% premarket.
• Consumers have accused the two companies of knowingly hiding the risk of necrotizing enterocolitis associated with the products. They are still facing more than 1,000 lawsuits over the issue.
• In a note, JP Morgan called the verdict an "unexpected win," adding that while many investors thought Abbott's exposure to NEC litigation would be in the $2B-$3B range, that amount could now be reduced by $500M-$1B.
• And while the next state and federal cases won't come until spring 2025, analyst Robbie Marcus said that "after today’s verdict and the overwhelming societal support of infant formula, we think it's prudent to lower the liability exposure and raise the odds of an Abbott victory in the trials, or at least improve the company’s negotiating power in a settlement."
• The firm rates Abbott overweight with a $135 price target (~19% upside based on Oct. 31 close).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。